Short answer
Cartesian Therapeutics, Inc. (RNAC) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results announced for quarter ended September 30, 2026.
Cartesian Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 financial results announced for quarter ended September 30, 2026
- Full results and management commentary available in Exhibit 99.1
- Investor focus: cash position, clinical-program spending, and development updates in the accompanying release
Item EX-99.1 · Exhibit EX-99.1
- Q3 net loss $11.5M, or $0.38 per share, versus $35.9M, or $1.38, in Q3 2025
- Cash $124.7M, including $50M K2HV financing, expected to fund operations into 2028
- AURORA Phase 3 MG data expected 1Q27, with BLA submission planned for mid-2027
- Retreatment data showed mean MG-ADL reduction of 6.6 points at Month 12, with no new safety signals
- TRITON and HELIOS data expected 1H27, creating additional 2027 clinical catalysts beyond MG
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Cartesian Therapeutics, Inc. 8-K filings
Get the next RNAC 8-K as it lands
Follow RNAC for push alerts, or ask the research agent what this filing means.